Newsletter
| Promoter: | Stock Shock and Awe | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ETBI | $2000 | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: 0.00 % | |
| *We think that this promoter is a part of a group of promoters. | ||
 |
 |
|
Eastgate Biotech Corp (ETBI)
Traders,
We found a new biotech play today that we think is ready to run - Eastgate Biotech (ETBI)
ETBI looks to have found strong support after pulling back over the past several weeks.
And priced at just $0.03 with a small market cap of around $2m, ETBI could be about to fly high.
What does ETBI do you ask?
ETBI is developing a way to deliver insulin by way of a tablet.
Both the nutraceutical and pharmaceutical industries are consistently looking out for innovative products that manage sugar in diabetes patience.
Glucora is the answer.
Glucora is a natural based formula in self-emulsifying delivery system that provides support for healthy glucose metabolism.
Used for the development of novel formulations and alternative dosage forms of existing biologically active molecules, Glucora receives an NPN (Natural Product Number 80057426 ) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
Data from the Centers for Disease Control and Prevention notes that 26 some million people currently have diabetes -- with about 90% to 95% of those cases being Type 2..
The world's population is aging fast, technology is improving, and public demand for more effective medications with fewer side effects is growing.
Global Industry Analysts projected the global market could be worth 10.1 billion dollars by 2017.
This is where ETBI comes in. Their R&D strategy and product analysis include the identification of biologically active compounds having limited absorption due to low solubility.
EastGate Biotech's technology platform provides an effective delivery system with increased bioavailability of incorporated compounds.
The Company's approach increases solubility of hydrophobic compounds in a proprietary self-emulsifying vehicle using a safe combination of known and approved excipients.
To date, Eastgate's sub-micron self-emulsifying delivery platform has been used for improvement of dietary supplements as well as pharmaceutical products.
The Biotech sector is unique; however, Eastgate's technology extends beyond and places the Company into the Nutraceutical space. Eastgate's products are patient friendly by design; they taste well and come in different forms and they are also designed to allow for the body to fully absorb the key pharmaceutical ingredients it needs.
Eastgate recently signed a licensing agreement with New Jersey based Purine Pharma, LLC ('Purine') to produce and distribute Eastgate's line of nutraceuticals under its own private label. Purine supplies a line of over 200 over-the-counter and prescription based cold, allergy, analgesic, topical and vitamin and supplement products, opening up Eastgate's opportunities to market and distribute their products in North America and internationally.
EastGate Biotech Provides Update On Its Patent PortfolioSALT LAKE CITY and TORONTO, Feb. 3, 2015 /PRNewswire/ -- EastGate Biotech Corp. (ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology. The company recently expanded its new pharmaceutical product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome. In order to protect our innovation and know-how the company had filed these initial provisional patents: US 61/947,678 Title: Pharmaceutical Composition for Transmucosal Delivery US 61/947,698 Title: Treatment of Diabetes and Metabolic Syndrome These two provisional patents relate specifically to the company's intraoral insulin formulation. The company has outlined its sub-micron self-nanoemulsifying platform technology to develop alternative dosage forms for delivery of known biologically active molecules. These technological approaches have demonstrated robustness and resulted in diversification of drug delivery products. As a result, the company was able to develop an intraoral insulin tablet that is delivered to the mouth for intraoral insulin absorption (not GI-tract delivery). The company will continue to prepare additional patent application filings in order to bolster the intellectual property and know-how of the intraoral insulin tablet and its other dosage forms. The company already has patents for its intraoral Lorazepam Spray for acute seizures: PCT/C2014/000126 Title: Pharmaceutical Composition for Transmucosal Administration of Benzodiazepines PCT/CA2014/000127 Title: Pharmaceutical Composition For Enhanced Transmucosal Administration of Benzodiazepines The company plans on expanding the patent portfolio for this indication as the clinical and scale-up manufacturing development continues. "We are pleased with the expansiveness of our patent portfolio for our pharmaceutical products", says Anna Gluskin, CEO of EastGate Biotech Corp. "The company's intent is to commercially-realize our unique sub-micron self-nanoemusifying delivery system and the breadth of the Intellectual Property will open the doors to licensing partners interested in innovative drugs in the highly diverse marketplace", continues Gluskin.
Read this news in full at http://finance.yahoo.com/news/eastgate-biotech-provides-patent-portfolio-143000718.html
In a nutshell...
With 50 million diagnosed - and 50 million undiagnosed - diabetes sufferers in North America alone gives an indication of the enormous market potential for ETBI's new insulin tablet.
Revolutionary treatment options, like the one Eastgate Biotech Corp are developing could become excellent in combination therapies that further enhance the effectiveness of existing medications and could, ultimately, give existing companies producing type 2 diabetes medications a chance to extend the revenue lifetime of their drug through combinations.
Joe
www.StockShockandAwe.com
Follow Us On
  |
|
|
-------------------------------------------------------------------------------- DISCLAIMER ---------------------------------------------------------------------------------- Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stockshockandawe.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in Stockshockandawe.com statements and opinions and such statements and opinions cannot be considered independent. Stockshockandawe.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, Stockshockandawe.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. Stockshockandawe.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile.
Stockshockandawe.com has been compensated via wire transfer or electronic payment up to two thousand dollars from a non-affiliated third party for this profile of ETBI Stockshockandawe.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated Stockshockandawe.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If Stockshockandawe.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.
|